167 related articles for article (PubMed ID: 37602699)
1. Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer.
Gao X; Han W; Chen L; Li H; Zhou F; Bai B; Yan J; Guo Y; Liu K; Li W; Li R; Yuan Q; Zhang J; Lu Y; Zhao X; Ji G; Li M; Zhao Q; Wu K; Li Z; Nie Y
Cancer Med; 2023 Sep; 12(17):17613-17631. PubMed ID: 37602699
[TBL] [Abstract][Full Text] [Related]
2. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
3. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of the effect of Helicobacter pylori on the expressions of SOX2, CDX2, MUC2, MUC5AC, MUC6, TFF1, TFF2, and TFF3 mRNAs in human gastric carcinoma cells.
Matsuda K; Yamauchi K; Matsumoto T; Sano K; Yamaoka Y; Ota H
Scand J Gastroenterol; 2008 Jan; 43(1):25-33. PubMed ID: 18938748
[TBL] [Abstract][Full Text] [Related]
5. The relationship among PDX1, CDX2, and mucin profiles in gastric carcinomas; correlations with clinicopathologic parameters.
Oz Puyan F; Can N; Ozyilmaz F; Usta U; Sut N; Tastekin E; Altaner S
J Cancer Res Clin Oncol; 2011 Dec; 137(12):1749-62. PubMed ID: 21909647
[TBL] [Abstract][Full Text] [Related]
6. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
7. Mucin-Phenotype and Expression of the Protein V-Set and Immunoglobulin Domain Containing 1 (VSIG1): New Insights into Gastric Carcinogenesis.
Satala CB; Jung I; Gurzu S
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240039
[TBL] [Abstract][Full Text] [Related]
8. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype.
Walsh MD; Clendenning M; Williamson E; Pearson SA; Walters RJ; Nagler B; Packenas D; Win AK; Hopper JL; Jenkins MA; Haydon AM; Rosty C; English DR; Giles GG; McGuckin MA; Young JP; Buchanan DD
Mod Pathol; 2013 Dec; 26(12):1642-56. PubMed ID: 23807779
[TBL] [Abstract][Full Text] [Related]
9. CDX2 expression is increased in gastric cancers with less invasiveness and intestinal mucin phenotype.
Ha Kim G; Am Song G; Youn Park D; Han Lee S; Hyun Lee D; Oh Kim T; Jae Jo H; Heo J; Hwan Kang D; Cho M
Scand J Gastroenterol; 2006 Aug; 41(8):880-6. PubMed ID: 16803685
[TBL] [Abstract][Full Text] [Related]
10. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
Alarid-Escudero F; Schrag D; Kuntz KM
Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
12. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.
Camilo V; Barros R; Celestino R; Castro P; Vieira J; Teixeira MR; Carneiro F; Pinto-de-Sousa J; David L; Almeida R
BMC Cancer; 2014 Oct; 14():753. PubMed ID: 25300947
[TBL] [Abstract][Full Text] [Related]
14. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic and immunohistochemical study on early gastric signet-ring cell carcinoma].
Xiong ZF; Xiao H; Tan YS
Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):442-6. PubMed ID: 21055171
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis.
Roessler K; Mönig SP; Schneider PM; Hanisch FG; Landsberg S; Thiele J; Hölscher AH; Dienes HP; Baldus SE
World J Gastroenterol; 2005 Jun; 11(21):3182-8. PubMed ID: 15929165
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
[TBL] [Abstract][Full Text] [Related]
18. Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study.
Gao X; Zhao L; Zhang N; Han W; Liu K; Yan J; Chen L; Pan Y; Li R; Li W; Zhang H; Li H; Wang S; Gao X; Niu P; Wang W; Ji G; Zhao Q; Lu Y; Li Z; Shang L; Liang H; Wu K; Deng J; Chen Y; Nie Y;
Int J Surg; 2023 May; 109(5):1330-1341. PubMed ID: 37037586
[TBL] [Abstract][Full Text] [Related]
19. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.
Jiang Y; Xie J; Han Z; Liu W; Xi S; Huang L; Huang W; Lin T; Zhao L; Hu Y; Yu J; Zhang Q; Li T; Cai S; Li G
Clin Cancer Res; 2018 Nov; 24(22):5574-5584. PubMed ID: 30042208
[No Abstract] [Full Text] [Related]
20. Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma.
Jun SY; Eom DW; Park H; Bae YK; Jang KT; Yu E; Hong SM
Mod Pathol; 2014 Oct; 27(10):1364-74. PubMed ID: 24603585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
